Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).

Min Zhu(Eye & ENT Hospital of Fudan University), Sameer Doshi(Amgen (United States)), Christian Brandl(Amgen (Germany)), Jessica Johnson(University of North Carolina at Chapel Hill), Andrea Kratzer(Amgen (Germany)), Indrajeet Singh(Janssen (United States)), Andreas Wolf(Amgen (Germany)), Chris Holland(Amgen (United States))
Journal of Clinical Oncology
May 20, 2015
10.1200/jco.2015.33.15_suppl.2561
Cited by 7

Related Papers

De novo mutations in schizophrenia implicate synaptic networks
|Nature|2014|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Gene expression elucidates functional impact of polygenic risk for schizophrenia
|Nature Neuroscience|2016|1.2k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869